Literature DB >> 3280182

Insulin responses and lymphocyte subclasses in children with newly diagnosed insulin-dependent diabetes.

T Scheinin1, J Mäenpää, S Koskimies, B M Dean, G F Bottazzo, S Kontiainen.   

Abstract

Children with newly diagnosed insulin-dependent diabetes mellitus (IDDM) had increased numbers of CD25 positive lymphocytes in peripheral blood and peripheral blood mononuclear cells responded to insulin antigens by proliferation. The CD25 positivity and insulin proliferation were associated to the duration of symptoms before the diagnosis of IDDM. Thus increased numbers of CD25 positive cells were found in 89% and insulin induced proliferation in 100% of patients with symptoms of diabetes of less than 1 week's duration before diagnosis, while CD25 positivity and insulin-induced proliferation were observed in 36% and 29% of children who had had symptoms for 4 weeks or more before diagnosis. Children with IDDM also had increased numbers of CD4 positive T cells in peripheral blood. The frequency of HLA-DR4 and HLA-DR3/4 in diabetic children was higher and that of HLA-DR2 lower than in the normal population. Insulin, islet cell, gastric-parietal cell, thyroid and antinuclear antibodies did not correlate to the duration of symptoms before diagnosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280182      PMCID: PMC1541653     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  A rapid micro-method for the phytohaemagglutinin-induced human lymphocyte transformation test.

Authors:  W J Penhale; A Farmer; A C Maccuish; W J Irvine
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

2.  Proliferative responses to insulin antigens in diabetics and controls.

Authors:  T Scheinin; L Groop; E Nikkilä; S Kontiainen
Journal:  J Clin Lab Immunol       Date:  1983-07

3.  Discrepancy in expression ability of Tac antigen and Ia determinants defined by monoclonal antibodies on activated or cultured cord blood T lymphocytes.

Authors:  T Yokoi; T Miyawaki; A Yachie; S Ohzeki; N Taniguchi
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

4.  Increased circulating Ia-antigen-bearing T cells in type I diabetes mellitus.

Authors:  R A Jackson; M A Morris; B F Haynes; G S Eisenbarth
Journal:  N Engl J Med       Date:  1982-04-01       Impact factor: 91.245

5.  A solution to the genetic and environmental puzzles of insulin-dependent diabetes mellitus.

Authors:  D D Adams; Y J Adams; J G Knight; J McCall; P White; R Horrocks; E van Loghem
Journal:  Lancet       Date:  1984-02-25       Impact factor: 79.321

6.  Coincident presence of thyro-gastric autoimmunity at onset of type 1 (insulin-dependent) diabetes.

Authors:  W J Riley; A Winer; D Goldstein
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

7.  Culture and phenotype of activated T-cells from patients with type I diabetes mellitus.

Authors:  A R Hayward; M Herberger
Journal:  Diabetes       Date:  1984-04       Impact factor: 9.461

8.  Alterations of peripheral T-lymphocyte subpopulations in patients with insulin-dependent (type 1) diabetes mellitus.

Authors:  K Buschard; C Röpke; S Madsbad; J Mehlsen; T B Sørensen; J Rygaard
Journal:  J Clin Lab Immunol       Date:  1983-03

9.  Complement-fixing islet-cell antibodies in type-I diabetes: possible monitors of active beta-cell damage.

Authors:  G F Bottazzo; B M Dean; A N Gorsuch; A G Cudworth; D Doniach
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

10.  The genetic susceptibility to type 1 (insulin-dependent) diabetes: analysis of the HLA-DR association.

Authors:  E Wolf; K M Spencer; A G Cudworth
Journal:  Diabetologia       Date:  1983-04       Impact factor: 10.122

View more
  1 in total

1.  Selective activation of T cells in newly diagnosed insulin-dependent diabetic patients: evidence for heterogeneity of T cell receptor usage.

Authors:  S Kontiainen; R Toomath; J Lowder; M Feldmann
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.